Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Laura Francis Biography and Net Worth

Director of Shockwave Medical

Laura A. Francis has served as our Chief Executive Officer and a Director on our Board since April 2021. As our Chief Financial Officer since May 2015 and Chief Operating Officer since July 2019, Ms. Francis played a fundamental role in bringing the company public in October 2018 and building the operations of the business. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with public and private life science companies, including Auxogyn, now part of Progyny (Nasdaq: PGNY), Promega Corporation, and Bruker Corporation (Nasdaq: BRKR). Earlier in her career, she was an Engagement Manager with McKinsey & Company and Audit Manager with Coopers & Lybrand, now PricewaterhouseCoopers. Ms. Francis has been a Director for Shockwave Medical (Nasdaq: SWAV) since January 2019, where she serves as Audit Committee Chair and Compensation Committee Member. She received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.

What is Laura Francis' net worth?: The estimated net worth of Laura Francis is at least $161.64 million as of November 18th, 2024. Mr. Francis owns 482,875 shares of Shockwave Medical stock worth more than $161,642,406 as of November 23rd. This net worth estimate does not reflect any other investments that Mr. Francis may own. Learn More about Laura Francis' net worth.
How do I contact Laura Francis?: The corporate mailing address for Mr. Francis and other Shockwave Medical executives is 5403 Betsy Ross Drive, Santa Clara CA, 95054. Shockwave Medical can also be reached via phone at (877) 775-4846 and via email at [email protected]. Learn More on Laura Francis' contact information.
Has Laura Francis been buying or selling shares of Shockwave Medical?: Laura Francis has not been actively trading shares of Shockwave Medical during the last ninety days. Most recently, Laura Francis sold 1,500 shares of the business's stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $300.00, for a transaction totalling $450,000.00. Following the completion of the sale, the director now directly owns 3,551 shares of the company's stock, valued at $1,065,300. Learn More on Laura Francis' trading history.
Who are Shockwave Medical's active insiders?: Shockwave Medical's insider roster includes Colin Cahill (Director), Laura Francis (Director), Douglas Godshall (CEO), Antoine Papiernik (Director), Trinh Phung (VP), Dan Puckett (CFO), Maria Sainz (Director), Frank Watkins (Director), and Isaac Zacharias (Insider). Learn More on Shockwave Medical's active insiders.
Are insiders buying or selling shares of Shockwave Medical?: In the last year, insiders at the sold shares 21 times. They sold a total of 129,216 shares worth more than $30,809,995.81. The most recent insider tranaction occured on March, 26th when Director Laura Francis sold 1,500 shares worth more than $450,000.00. Insiders at Shockwave Medical own 3.4% of the company. Learn More about insider trades at Shockwave Medical.
Information on this page was last updated on 3/26/2024.

Laura Francis Insider Trading History at Shockwave Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/26/2024	Sell	1,500	$300.00	$450,000.00	3,551
2/16/2024	Sell	1,000	$250.00	$250,000.00	3,551
3/31/2022	Sell	1,890	$210.00	$396,900.00
3/29/2022	Sell	2,310	$195.33	$451,212.30
6/24/2021	Sell	1,500	$200.00	$300,000.00	2,701
6/14/2021	Sell	2,700	$186.01	$502,227.00	2,701

Laura Francis Buying and Selling Activity at Shockwave Medical

Shockwave Medical Company Overview

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Today's Range

Now: $334.75

$334.75

50 Day Range

MA: $332.85

$328.87

$334.83

2 Week Range

Now: $334.75

$157.00

$334.90

Volume

N/A

Average Volume

968,088 shs

Market Capitalization

$12.57 billion

P/E Ratio

78.21

Dividend Yield

N/A

Beta

0.88

Trump won. Buy this coin now.

From Weiss Ratings | Ad